Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 421827, 10 pages
http://dx.doi.org/10.1155/2014/421827
Research Article

BlockingαVβ3 Integrin Ligand Occupancy Inhibits the Progression of Albuminuria in Diabetic Rats

1Department of Medicine, UNC School of Medicine, Chapel Hill, NC 27599, USA
2Vascular Pharmaceuticals, Inc., 510 Meadowmont Village Circle, Suite 283, Chapel Hill, NC 27517, USA

Received 25 August 2014; Accepted 7 October 2014; Published 20 October 2014

Academic Editor: Francesco Chiarelli

Copyright © 2014 Laura A. Maile et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. S. Kanwar, L. Sun, P. Xie, F.-Y. Liu, and S. Chen, “A glimpse of various pathogenetic mechanisms of diabetic nephropathy,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 395–423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Turgut and W. K. Bolton, “Potential new therapeutic agents for diabetic kidney disease,” The American Journal of Kidney Diseases, vol. 55, no. 5, pp. 928–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. P. Nawroth and B. Isermann, “Mechanisms of diabetic nephropathy—old buddies and newcomers part 1,” Experimental and Clinical Endocrinology and Diabetes, vol. 118, no. 9, pp. 571–576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. C. Thomas and P.-H. Groop, “New approaches to the treatment of nephropathy in diabetes,” Expert Opinion on Investigational Drugs, vol. 20, no. 8, pp. 1057–1071, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Shepler, C. Nash, C. Smith, A. DiMarco, J. Petty, and S. Szewciw, “Update on potential drugs for the treatment of diabetic kidney disease,” Clinical Therapeutics, vol. 34, no. 6, pp. 1237–1246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Advani and R. E. Gilbert, “The endothelium in diabetic nephropathy,” Seminars in Nephrology, vol. 32, no. 2, pp. 199–207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Nakagawa, K. Tanabe, B. P. Croker et al., “Endothelial dysfunction as a potential contributor in diabetic nephropathy,” Nature Reviews Nephrology, vol. 7, no. 1, pp. 36–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. G. K. Kolluru, S. C. Bir, and C. G. Kevil, “Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing,” International Journal of Vascular Medicine, vol. 2012, Article ID 918267, 30 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Diez-Sampedro, O. Lenz, and A. Fornoni, “Podocytopathy in diabetes: a metabolic and endocrine disorder,” American Journal of Kidney Diseases, vol. 58, no. 4, pp. 637–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. A. Hamerski and S. A. Santoro, “Integrins and the kidney: biology and pathobiology,” Current Opinion in Nephrology and Hypertension, vol. 8, no. 1, pp. 9–14, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Dentelli, A. Rosso, A. Zeoli et al., “Oxidative stress-mediated mesangial cell proliferation requires RAC-1/reactive oxygen species production and β4 integrin expression,” The Journal of Biological Chemistry, vol. 282, no. 36, pp. 26101–26110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. V. K. Pedchenko, S. V. Chetyrkin, P. Chuang et al., “Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy,” Diabetes, vol. 54, no. 10, pp. 2952–2960, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. D. K. Jin, A. J. Fish, E. A. Wayner et al., “Distribution of integrin subunits in human diabetic kidneys,” Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 2636–2645, 1996. View at Google Scholar · View at Scopus
  14. S. B. Nicholas, J. Liu, J. Kim et al., “Critical role for osteopontin in diabetic nephropathy,” Kidney International, vol. 77, no. 7, pp. 588–600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Lu, M. Miao, T. R. Schoeb, A. Agarwal, and J. E. Murphy-Ullrich, “Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy,” American Journal of Pathology, vol. 178, no. 6, pp. 2573–2586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Li, M. Ren, N. Chen, M. Luo, Z. Zhang, and J. Wu, “Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions,” PLoS ONE, vol. 7, no. 5, Article ID e37195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. E. C. Miller, B. E. Capps, R. R. Sanghani, D. R. Clemmons, and L. A. Maile, “Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia,” Investigative Ophthalmology & Visual Science, vol. 48, no. 8, pp. 3878–3887, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. Maile, B. E. Capps, Y. Ling, G. Xi, and D. R. Clemmons, “Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I,” Endocrinology, vol. 148, no. 5, pp. 2435–2443, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. L. A. Maile, W. H. Busby, T. C. Nichols et al., “A monoclonal antibody against αVβ3 integrin inhibits development of atherosclerotic lesions in diabetic pigs,” Science Translational Medicine, vol. 2, no. 18, p. 18ra11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. L. A. Maile, J. Badley-Clarke, and D. R. Clemmons, “Structural analysis of the role β3 subunit of the αVβ3 integrin in IGF-I signaling,” Journal of Cell Science, vol. 114, no. 7, pp. 1417–1425, 2001. View at Google Scholar · View at Scopus
  21. F. Turgut and W. K. Bolton, “Potential new therapeutic agents for diabetic kidney disease,” American Journal of Kidney Diseases, vol. 55, no. 5, pp. 928–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. C. Thomas and P. H. Groop, “New approaches to the treatment of nephropathy in diabetes,” Expert Opinion on Investigational Drugs, vol. 20, no. 8, pp. 1057–1071, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. B. McGregor, S. Colon, M. Mutin, E. Chignier, P. Zech, and J. McGregor, “Thrombospondin in human glomerulopathies: a marker of inflammation and early fibrosis,” The American Journal of Pathology, vol. 144, no. 6, pp. 1281–1287, 1994. View at Google Scholar · View at Scopus
  24. T. Turk, J. W. Leeuwis, J. Gray et al., “BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression,” Journal of Histochemistry and Cytochemistry, vol. 57, no. 7, pp. 623–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Jim, M. Ghanta, A. Qipo et al., “Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study,” PLoS ONE, vol. 7, no. 5, Article ID e36041, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Cohen-Bucay and G. Viswanathan, “Urinary markers of glomerular injury in diabetic nephropathy,” International Journal of Nephrology, vol. 2012, Article ID 146987, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Oriente, S. Iovino, A. Cassese et al., “Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-β activity and TGF-β1 expression,” Diabetologia, vol. 52, no. 12, pp. 2642–2652, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. V. K. Pedchenko, S. V. Chetyrkin, P. Chuang et al., “Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy,” Diabetes, vol. 54, no. 10, pp. 2952–2960, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. B. Nicholas, J. Liu, J. Kim et al., “Critical role for osteopontin in diabetic nephropathy,” Kidney International, vol. 77, no. 7, pp. 588–600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Wang, X. Wu, T. M. Lincoln, and J. E. Murphy-Ullrich, “Expression of constitutively active cGMP-dependent protein kinase prevents glucose stimulation of thrombospondin 1 expression and TGF-β activity,” Diabetes, vol. 52, no. 8, pp. 2144–2150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. L. A. Maile, W. H. Busby, K. Sitko et al., “Insulin-like growth factor-i signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the β3-subunit of αVβ3,” Molecular Endocrinology, vol. 20, no. 2, pp. 405–413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. L. A. Maile, K. Gollahon, C. Wai, G. Byfield, M. E. Hartnett, and D. Clemmons, “Disruption of the association of integrin-associated protein (IAP) with tyrosine phosphatase non-receptor type substrate-1 (SHPS)-1 inhibits pathophysiological changes in retinal endothelial function in a rat model of diabetes,” Diabetologia, vol. 55, no. 3, pp. 835–844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long, “Abnormal angiogenesis in diabetic nephropathy,” Diabetes, vol. 58, no. 7, pp. 1471–1478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Yamamoto, Y. Maeshima, H. Kitayama et al., “Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy,” Diabetes, vol. 53, no. 7, pp. 1831–1840, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Ichinose, Y. Maeshima, Y. Yamamoto et al., “Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model,” Diabetes, vol. 54, pp. 2891–2903, 2005. View at Google Scholar
  36. S. X. Zhang, J. J. Wang, K. Lu, R. Mott, R. Longeras, and J. X. Ma, “Therapeutic potential of angiostatin in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 17, no. 2, pp. 475–486, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Ichinose, Y. Maeshima, Y. Yamamoto et al., “2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice,” Diabetes, vol. 55, no. 5, pp. 1232–1242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Nasu, Y. Maeshima, M. Kinomura et al., “Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy,” Diabetes, vol. 58, no. 10, pp. 2365–2375, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Saito, Y. Maeshima, T. Nasu et al., “Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis,” The American Journal of Physiology—Renal Physiology, vol. 300, no. 4, pp. F873–F886, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Santulli, M. F. Basilicata, M. de Simone et al., “Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit,” Journal of Translational Medicine, vol. 9, article 7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Wei, C. C. Moller, M. M. Altintas et al., “Modification of kidney barrier function by the urokinase receptor,” Nature Medicine, vol. 14, no. 1, pp. 55–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. F. C. Brosius III, C. E. Alpers, E. P. Bottinger et al., “Animal models of diabetic complications consortium. Mouse models of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 20, no. 12, pp. 2503–2512, 2009. View at Google Scholar
  43. L. A. Maile, W. H. Busby, K. A. Gollahon et al., “Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs,” Endocrinology, 2014. View at Google Scholar
  44. G. Santulli, E. Cipolletta, D. Sorriento et al., “CaMK4 gene deletion induces hypertension,” Journal of the American Heart Association, vol. 1, no. 4, Article ID e001081, 2012. View at Publisher · View at Google Scholar · View at Scopus